Clinical trial
Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer
NCT00203502 · University of Arkansas, Other · Completed
Key facts
| NCT number | NCT00203502 |
|---|---|
| Title | Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer |
| Official title | Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorubicin in Operable/Locally Advanced Breast Cancer |
| Lead sponsor | University of Arkansas, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Cyclophosphamide, Docetaxel |
| Enrollment | 40 |
| Start date | Sep 1, 2005 |
| Primary completion | Feb 1, 2015 |
| Completion | Feb 1, 2015 |
| First posted | Sep 20, 2005 |
| Last update posted | May 11, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: